Teva Pharmaceutical Industries announced positive results for its Treanda drug trial, for the treatment of lymphoma. During the trial, Treanda was given to patients with slow-growing lymphoma (non-Hodgkin lymphoma), in combination with Roche’s Rituxan. Results showed that patients treated with the combined drugs lived three years longer with no progression of their tumors, compared to those taking chemotherapy with Rituxan.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments